|Webcasts|December 8, 2021
Embarking on the biotech journey: how to build a long-term plan for successful drug development
Author(s)IQVIA Biotech
Wednesday December 8, 2021 at 11am EST | 8am PST | 4pm GMT | 5pm CET Join this webinar to learn how to approach the early stages of drug development and build a long-term plan to advance your drug to market.
Advertisement
Event Overview:
Biotech and biopharma companies continue to drive the drug development pipeline, and despite a global pandemic, many small, nimble sponsors remain strong in funding levels and drug approvals. Still, with increased investment in the biotech sector, competition for visibility and resources is fierce.
For many small sponsors, the number of questions to ask and decisions to make can be overwhelming. Leveraging data and expertise to support a strategic drug development plan can mean the difference between success and failure.
Join this webinar to learn how to approach the early stages of drug development and build a long-term plan to advance your drug to market.
Key Learning Objectives:
- Gain tips on how to avoid the pitfalls of early clinical development
- Discover insights from a team with experience leading hundreds of biotech programs
- Learn how to build a clinical development strategy aligned to regulatory, payer, and commercial requirements
Speakers
Megan Hooton
Chief Operating Officer
IQVIA Biotech
Chief Operating Officer
IQVIA Biotech
Megan Hooton brings a wealth of operational and cross-cultural expertise to the role of Chief Operating Officer at IQVIA Biotech, having more than 30 years of experience managing global research and development operations across pharmaceutical and biotech segments.
Meg joined IQVIA in 2008 and has served in clinical operations and project management roles, initially in her native Australia, and later managed the North Asia Therapeutic Delivery Unit. She served as Vice President and Head of Global Project Leadership and Regulatory Start-up for the Asia-Pacific region before becoming the Global Therapeutic Area Head for Oncology in 2017.
Meg started her career as a Registered Nurse, and after stints in the private sector, academia, and the Royal Australian Navy Reserve, she joined the clinical team at Bristol-Myers Squibb in the oncology and immunology franchises. In addition to her nursing degree and specialization in Intensive Care and Coronary Care, Meg has a bachelor's degree in Asian Studies from Monash University.
Michael Kardas
Vice President and Global Head of the Strategic Drug Development Group
IQVIA
Vice President and Global Head of the Strategic Drug Development Group
IQVIA
Michael Kardas, PharmD is Vice President and Global Head of the Strategic Drug Development Group at IQVIA. Dr. Kardas has more than 20 years of experience in the biopharma industry and provides expert advice to biopharmaceutical companies in the data driven design and development of their clinical program. He earned his B.A. degree in Biology from College of the Holy Cross and completed his Doctor of Pharmacy degree from the University of Connecticut.
Newsletter
Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.
Advertisement
Related Articles
- The Impact of ICH E6(R3) on Biospecimen Management
June 25th 2025
- The Top 5 Myths About eCOAs In 2025
March 25th 2025
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
Investigational PD-L1 x VEGF-A Bispecific Antibody Demonstrates Strong Overall Response Rate in Phase II Small Cell Lung Cancer Trial
2
Phase III BRUIN CLL-313 Trial Finds Jaypirca Extends Progression-Free Survival in Treatment-Naïve CLL/SLL
3
FDA Fast Tracks Sanofi’s Intravitreal Gene Therapy for Neovascular Age-Related Macular Degeneration
4
How Recent Policy Changes Could Impact Clinical Research
5